Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2336805 dose-ranging study with pegylated interferon and ribavirin in treatment-naive chronic genotype 1 or 4 hepatitis C
2012-000523-40Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of GSK2336805 in hepatitis C virus infection (2 arms), sponsored by GSK. Primary endpoint: 12-week safety and tolerability. Started Jul 2012; status: completed.
02
Drugs
GSK2336805
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2012-000523-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000523-40.